CA
NZ
UK
AU
IND
US
…
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -147.24M | -55.11M | -26.98M | - |
| Minority interest | 40.10M | - | - | - |
| Net income | -148.13M | -55.15M | -26.75M | - |
| Selling general administrative | 70.94M | 8.86M | 5.98M | - |
| Reconciled depreciation | 3.04M | 1.98M | 0.96M | - |
| Ebit | -153.01M | -55.11M | -27.02M | -19.16M |
| Ebitda | -143.99M | -53.13M | -26.02M | - |
| Depreciation and amortization | 9.02M | 1.98M | 1.01M | - |
| Non operating income net other | 5.98M | - | - | - |
| Operating income | -153.01M | -55.11M | -27.02M | - |
| Other operating expenses | 153.01M | 55.11M | 27.02M | - |
| Interest expense | 0.21M | 0.00M | 0.04M | 0.00M |
| Tax provision | 0.90M | 0.04M | -0.23M | - |
| Interest income | 5.98M | 0.00M | 0.04M | - |
| Net interest income | 5.77M | 0.00M | 0.04M | - |
| Income tax expense | 0.90M | 0.04M | -0.23M | 0.36M |
| Total revenue | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 153.01M | 55.11M | 27.02M | - |
| Total other income expense net | 5.77M | 0.00M | 0.04M | - |
| Net income from continuing ops | -148.13M | -55.15M | -26.75M | - |
| Net income applicable to common shares | -188.24M | -55.15M | -26.75M | -79.61M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 420.55M | 518.00M | 40.30M | 16.70M | - |
| Intangible assets | - | 0.21M | - | - | - |
| Other current assets | 9.82M | 1.38M | 0.03M | 0.05M | - |
| Total liab | 29.22M | 13.06M | 13.38M | 6.84M | - |
| Total stockholder equity | -1103.40M | -1096.62M | 26.92M | 9.86M | - |
| Other current liab | 22.76M | 7.34M | 9.21M | 4.50M | 0.35M |
| Common stock | 0.02M | 0.02M | 188.43M | 116.23M | 95.50M |
| Capital stock | 0.02M | 0.02M | 188.43M | 116.23M | - |
| Retained earnings | -1139.66M | -1104.12M | -161.51M | -106.36M | -79.61M |
| Cash | 60.65M | 490.25M | 20.56M | 4.58M | - |
| Total current liabilities | 25.04M | 10.87M | 12.31M | 5.50M | 2.71M |
| Current deferred revenue | -3.63M | - | - | - | - |
| Net debt | -56.24M | -487.85M | -19.22M | -3.02M | - |
| Short term debt | 0.80M | 0.49M | 0.27M | 0.23M | - |
| Short long term debt total | 4.41M | 2.40M | 1.33M | 1.56M | - |
| Other stockholder equity | 36.11M | 7.48M | 249.76M | - | - |
| Property plant equipment | - | 10.71M | 12.60M | 10.47M | 3.33M |
| Total current assets | 374.15M | 504.72M | 27.27M | 5.58M | 15.42M |
| Net tangible assets | - | 504.94M | 26.49M | 9.22M | 15.03M |
| Short term investments | 302.30M | - | - | - | - |
| Net receivables | 1.38M | - | - | - | - |
| Accounts payable | 5.10M | 3.04M | 2.83M | 0.78M | 0.48M |
| Accumulated other comprehensive income | 0.13M | - | - | - | - |
| Common stock total equity | - | 0.02M | - | - | - |
| Retained earnings total equity | - | -1104.12M | - | - | - |
| Non current assets total | 46.41M | 13.28M | 13.03M | 11.12M | - |
| Capital lease obligations | 4.41M | 2.40M | 1.33M | 1.56M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -1.74M | -5.19M | -5.46M | - |
| Change to liabilities | 0.77M | 7.87M | 0.68M | 1.20M |
| Total cashflows from investing activities | -1.74M | -5.19M | -5.46M | -2.97M |
| Net borrowings | - | -0.03M | -0.01M | -0.01M |
| Total cash from financing activities | 548.52M | 71.47M | 19.99M | 20.00M |
| Change to operating activities | -7.23M | -5.70M | -0.81M | -0.12M |
| Net income | -148.13M | -55.15M | -26.75M | -79.61M |
| Change in cash | 469.69M | 15.98M | -10.65M | -59.77M |
| Begin period cash flow | 20.56M | 4.58M | 15.23M | - |
| End period cash flow | 490.25M | 20.56M | 4.58M | 15.23M |
| Total cash from operating activities | -77.09M | -50.30M | -25.18M | -76.81M |
| Depreciation | 3.04M | 1.98M | 0.96M | 0.87M |
| Other cashflows from investing activities | 0.11M | 0.11M | 0.11M | 0.11M |
| Sale purchase of stock | 542.50M | - | - | - |
| Other cashflows from financing activities | 583.55M | 71.50M | 20.00M | 542.50M |
| Change to netincome | 74.47M | 0.70M | 0.73M | 0.50M |
| Capital expenditures | 1.85M | 5.19M | 5.46M | 1.30M |
| Cash flows other operating | -7.23M | - | - | - |
| Cash and cash equivalents changes | 469.69M | - | - | - |
| Change in working capital | -6.46M | 2.16M | -0.13M | - |
| Stock based compensation | 74.47M | 0.70M | 0.73M | - |
| Free cash flow | -78.94M | -55.49M | -30.64M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| PROK ProKidney Corp. |
0.05 4.67% |
1.12 | - | - | - | 91.32 | 1.99 |
| NVO Novo Nordisk A/S |
1.99 4.95% |
42.18 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.28 3.44% |
549.04 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-41.91 4.31% |
931.45 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
2000 Frontis Plaza Blvd., Winston-Salem, NC, United States, 27103
336 999 7028
163
| Name | Title | Year Born |
|---|---|---|
| Dr. Timothy A. Bertram D.V.M., Ph.D. | Founder, CEO & Director | 1955 |
| Mr. James Coulston CPA | Chief Financial Officer | 1976 |
| Dr. Deepak Jain Ph.D. | Chief Operating Officer | 1954 |
| Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | Sr. VP of Investor Relations | NA |
| Mr. Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer & Corp. Sec. | 1965 |
| Dr. Libbie P. McKenzie M.D. | Chief Medical Officer | 1973 |
| Ms. Ashley H. Johns | Sr. VP of Clinical Operations | NA |
| Dr. Joseph M. Stavas M.D. | Sr. VP of Clinical Devel. | NA |
| Dr. Darin J. Weber Ph.D. | Sr. VP of Regulatory Devel. | 1968 |
| Dr. Kerry Cooper M.D. | Sr. VP of Medical Affairs | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+2.10%
Communication Services
+1.48%
Consumer Cyclical
+2.12%
Consumer Defensive
+1.59%
Energy
-2.52%
Financial Services
+1.11%
Financials
-6.05%
Healthcare
+2.12%
Industrials
-0.12%
Real Estate
+1.25%
Technology
-0.07%
Utilities
+0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...